Showing 1451-1460 of 5603 results for "".
Do You Need to Provide a Good Faith Estimate for a Botox Treatment?
https://reachmd.com/topics/injectables/do-you-need-to-provide-a-good-faith-estimate-for-a-botox-treatment/35210/Recent updates from CMS still don’t mention aesthetics specifically, but there are indications that some aesthetic and dermatology services require a GFE.Guselkumab in Skin of Color: Results from a Randomized Phase 3b Psoriasis Trial
https://reachmd.com/programs/dermconsult/guselkumab-in-skin-of-color-results-from-a-randomized-phase-3b-psoriasis-trial/36371/Roflumilast Foam for Psoriasis: Efficacy, Tolerability, and Clinical Relevance
https://reachmd.com/programs/dermconsult/roflumilast-foam-for-psoriasis-efficacy-tolerability-and-clinical-relevance/36370/Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
https://reachmd.com/programs/spotlight-attr-cm/vutrisiran-for-attr-cm-exploring-an-rnai-therapeutic/32419/Read about recent clinical trial findings on vutrisiran, an RNA interference therapeutic that has emerged as a potential option for patients with transthyretin amyloid cardiomyopathy.Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
https://reachmd.com/programs/neurofrontiers/clemastine-fumarate-and-progressive-ms-a-closer-look-at-unexpected-risks-and-mechanisms/32825/Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
https://reachmd.com/programs/clinicians-roundtable/reframing-palliative-care-in-pah-early-integration-to-improve-outcomes/56326/Validating hf-PGA for Hand and Foot Psoriasis Severity in Adults
https://reachmd.com/programs/dermconsult/hf-pga-hand-foot-psoriasis-severity-adults/39681/Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
https://reachmd.com/programs/project-oncology/harnessing-the-immune-power-a-uniquely-designed-pd-1-inhibitor-for-esophageal-cancer/35512/Esophageal cancer is the tenth most common cancer worldwide and the sixth most prevalent cause of death due to cancer, which is why having additional treatment options for this disease is crucial.1 One available option, tislelizumab plus platinum-based chemotherapy, was recently approved by the FDAOn the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
https://reachmd.com/programs/project-oncology/io-therapies-for-patients-with-her2-negative-ggejc/35513/For patients who are diagnosed with metastatic gastric cancer, the five-year overall survival rate is roughly seven percent, underscoring the need for additional treatment options.1 Fortunately, there has been advancement in gastric cancer care, including the FDA approval of tislelizumab plus platinEnlisting Students in the Fight Against COVID-19: Helpful or Harmful?
https://reachmd.com/programs/covid-19-frontlines/enlisting-students-fight-against-covid-19-helpful-or-harmful/11325/Medical students are increasingly being thrust into frontline efforts to combat COVID-19. Will this help stem the tide, or compound the crisis?